Review of Operations Directors’ Report Chairman’s Letter CEO’s Report Financial Report Shareholder Information 3 Annual Report 2025 Dr Leearne Hinch CEO EXOSOME ISOLATION TOOLS DELIVERING REVENUE AND COLLABORATIONS INOVIQ’s best-in-class EXO-NET® exosome isolation technology for biomarker discovery and diagnostics is commercially available worldwide through our global distribution partner, Promega Corporation, delivering revenue and collaborations. Our research tool portfolio was expanded with the development and validation of NEURO-NET™ for isolating brain-derived exosomes from blood samples of Alzheimer’s and Parkinson’s patients. NEURO-NET broadens INOVIQ’s research tool portfolio and partnering opportunities for novel neurological diagnostics. EXOSOME DIAGNOSTIC ADVANCING TOWARD COMMERCIALISATION Our EXO-OC™ ovarian cancer screening test addresses a critical unmet need for early detection in asymptomatic, averagerisk women. Recent results demonstrated 77% overall sensitivity at >99.6% specificity, and 100% detection of early-stage I and II ovarian cancers. Leveraging our proprietary EXO-NET® technology, strategic collaborations and a staged regulatory approach, INOVIQ is preparing for rapid US commercialization as a Laboratory Developed Test (LDT), followed by global In Vitro Diagnostic (IVD) rollout to expand market access, support reimbursement and drive future revenue growth. EXOSOME THERAPEUTIC PROGRESSING TOWARD IN VIVO MILESTONE INOVIQ is developing next-gen exosome therapeutics engineered to target and destroy solid tumours. Our lead CAR-exosome therapy program aims to deliver potential cost, logistics, safety and efficacy advantages over autologous CAR-T therapies for solid tumours. In vitro studies demonstrated that CARNK-exosomes killed 88% of triple negative breast cancer cells in vitro. First in vivo data in a TNBC mouse model are expected in Q4 CY2025, informing our development plans and enabling potential pharmaceutical partnering discussions. SUBB2M PROGRAM ADVANCING WITH A PARTNERING FOCUS Our SubB2M technology has been analytically and clinically validated to detect breast cancer across all stages (81% sensitivity and 93% specificity), key breast cancer types and subtypes, and is effective for breast cancer monitoring. A peer-reviewed publication on the neuCA15-3 test in May 2025 reinforces the scientific robustness of the SubB2M technology and test performance. We are advancing product development to transfer the test onto an automated instrument platform to facilitate scalability and discussions with strategic partners for commercialisation. FUTURE MILESTONES DELIVERING VALUE INOVIQ is positioned as a leader in exosome technology, focused on delivering sustainable growth and shareholder value as we advance our pipeline toward key development and commercial milestones. In FY26, we expect to deliver key milestones, including commercial expansion of our EXO-NET® research tools, development progress across our exosome diagnostic and therapeutic programs, and strategic partnerships to accelerate commercialisation of our diagnostic technologies.
RkJQdWJsaXNoZXIy MjE2NDg3